Alexion Pharmaceuticals (ALXN) : On Friday, The money flowed into the Alexion Pharmaceuticals (ALXN) stock with an uptick to downtick ratio was recorded at 1.09. Transactions worth $37.61 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $34.58 million. The total money flow into the stock was $3.03 million. The block trades reveal a bullish bias with an up-down ratio of 2.68. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $8.38 million of block transactions on upticks. The value of block trades on downticks was $3.13 million, indicating lower selling interest. The total money flow in block trades was $5.25 million. In terms of price action, Alexion Pharmaceuticals (ALXN) traded down $1.96 during the session at $123.67. Compared to the previous days closing, the stock was down only by -1.56%. For the week, the stock is -4.6%, over previous weeks closing.
The company Insiders own 4.41% of Alexion Pharmaceuticals shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.53% . Institutional Investors own 96.48% of Alexion Pharmaceuticals shares. During last six month period, the net percent change held by insiders has seen a change of -1.08%.
In a related news, The Securities and Exchange Commission has divulged that ONeill Julie, officer (EVP. Global Operations) of Alexion Pharmaceuticals Inc, had unloaded 650 shares at an average price of $126.29 in a transaction dated on September 2, 2016. The total value of the transaction was worth $82,089.
Alexion Pharmaceuticals (NASDAQ:ALXN): stock was range-bound between the intraday low of $123.56 and the intraday high of $126.29 after having opened at $126.29 on Fridays session. The stock finally closed in the red at $126.29, a loss of -1.56%. The stock remained in the red for the whole trading day. The total traded volume was 1,083,049 shares. The stock failed to cross $126.29 in Fridays trading. The stocks closing price on Thursday was $125.63.
Alexion Pharmaceuticals (ALXN) : During the past 4 weeks, traders have been relatively bearish on Alexion Pharmaceuticals (ALXN), hence the stock is down -9.68% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -5.08% relative to the S&P 500. The 4-week change in the price of the stock is -9.8% and the stock has fallen -4.6% in the past 1 week.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.